Chiusura precedente | 2,9900 |
Aperto | 2,9900 |
Denaro | 3,0700 x 200 |
Lettera | 3,1300 x 100 |
Min-Max giorno | 2,9900 - 3,1300 |
Intervallo di 52 settimane | 2,5700 - 4,1390 |
Volume | |
Media Volume | 206.347 |
Capitalizzazione | 219,201M |
Beta (5 anni mensile) | 0,69 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,7400 |
Prossima data utili | 03 mag 2024 - 07 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 7,33 |
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a presentation at the Jefferies Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023, at 3:30 p.m. ET in New York. A live webcast of the Jefferies presentation can be accessed through the Events & Presentation
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that it will host a Research & Development (R&D) Day investor event on Monday, October 2, 2023. The event will take place at the Company’s headquarters in New York’s Hudson Yards from 12:00 pm - 2:30 pm and will be webcast simultaneously. Ovid management w
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET in New York, New York. A live webcast of the Cantor Fitzgerald presentation can be accessed